Results of a multicenter phase II trial for older patients with c-Kit positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C (LDAC) and imatinib.

被引：1
|
作者：
Heidel, F
Cortes, J
Ruecker, F
Kaufmann, M
Aulitzky, W
Letvak, L
Kindler, T
Huber, C
Dohner, H
Kantarjian, H
Fischer, T
机构：
[1] Univ Hosp Mainz, Mainz, Germany
[2] Univ Hosp Ulm, Ulm, Germany
[3] Robert Bosch Krankenhaus, Stuttgart, Germany
[4] Novartis Pharm Corp, E Hanover, NJ USA
[5] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
BLOOD | 2005年 / 106卷 / 11期
关键词：
D O I：
10.1182/blood.V106.11.1853.1853
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1853
引用
收藏
页码：527A / 527A
页数：1
相关论文
共 50 条
  • [21] A Randomised Evaluation of Low-Dose Ara-C Plus BCT-100 Versus Low Dose Ara-C in Older Patients with Acute Myeloid Leukaemia: Results from the LI-1 Trial
    Mussai, Francis J.
    Thomas, Ian
    Ariti, Cono
    Upton, Laura
    Sydenham, Mia
    Burnett, Alan K.
    Knapper, Steve
    Mehta, Priyanka
    McMullin, Mary Frances
    Copland, Mhairi
    Russell, Nigel H.
    Hills, Robert
    BLOOD, 2021, 138
  • [22] PHASE I/II STUDY OF VOSAROXIN AND DECITABINE IN NEWLY DIAGNOSED OLDER PATIENTS (PTS) WITH ACUTE MYELOID LEUKEMIA (AML) AND HIGH-RISK MYELODYSPLASTIC SYNDROME (MDS)
    Daver, N.
    Kantarjian, H.
    Garcia-Manero, G.
    Jabbour, E.
    Borthakur, G.
    Pierce, S.
    Vaughan, K.
    Vaughan, K.
    Ning, J.
    Gonzalez, G.
    Pemmarjau, N.
    Kadia, T.
    Konopleva, M.
    Andreeff, M.
    DiNardo, C.
    Cortes, J.
    Ward, R.
    Craig, A.
    Ravandi, F.
    HAEMATOLOGICA, 2016, 101 : 187 - 188
  • [23] A phase II pilot study of Gleevec/Glivec (imatinib mesylate, STI-571) in patients with c-kit positive acute myeloid leukemia (AML).
    Fischer, T
    Beck, J
    Duyster, J
    Peschel, C
    Müller-Navia, J
    Jäger, E
    Knuth, A
    Gschaidmeier, H
    Huber, C
    BLOOD, 2002, 100 (11) : 561A - 561A
  • [24] Phase I/II study of vosaroxin and decitabine in older patients (pts) with acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS)
    Daver, Naval
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    Pemmaraju, Naveen
    Kadia, Tapan
    DiNardo, Courtney
    Jain, Nitin
    Borthakur, Gautum
    Cortes, Jorge
    Adam, Craig
    Ravandi, Farhad
    CANCER RESEARCH, 2014, 74 (19)
  • [25] Adaptive randomization of idarubicin and Ara-C (IA) ± interleukin (IL11) in patients with newly diagnosed (ND) acute Myelogenous leukemia (AML) or high-risk Myelodysplastic syndrome (MDS)
    Tsimberidou, AM
    Estey, E
    Cortes, J
    Thomas, D
    Garcia-Manero, G
    Faderl, S
    Verstovsek, S
    O'Brien, S
    Kantarjian, R
    Giles, F
    BLOOD, 2002, 100 (11) : 264B - 264B
  • [26] Results of combination chemotherapy with topotecan and high-dose cytosine arabinoside (ara-C) in previously untreated patients with high-risk myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML).
    Beran, M
    Kantarjian, H
    Keating, M
    OBrien, S
    Pierce, S
    Koller, C
    Cortes, J
    Andreeff, M
    Kornblau, S
    Estey, E
    BLOOD, 1997, 90 (10) : 2593 - 2593
  • [27] Effect of hematologic improvement (HI) on survival in patients (pts) given targeted therapy (TT) as initial treatment of acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS)
    Yanada, M.
    Huang, X.
    O'Brien, S.
    Garcia-Manero, G.
    Ravandi, F.
    Borthakur, G.
    Issa, J.
    Giles, F.
    Kantarjian, H.
    Estey, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [28] Phase II Study of Vorinostat in Combination with Idarubicin (Ida) and Cytarabine (ara-C) as Front Line Therapy in Acute Myelogenous Leukemia (AML) or Higher Risk Myelodysplastic Syndrome (MDS).
    Garcia-Manero, Guillermo
    Tambaro, Francesco Paolo
    Bekele, B. Nebiyou
    Jabbour, Elias
    Ravandi, Farhad
    Yang, Hui
    Borthakur, Gautam
    Kadia, Tapan
    Cortes, Jorge
    Faderl, Stefan
    Konopleva, Marina
    Pierce, Sherry
    Burger, Jan A.
    Estrov, Zeev
    O'Brien, Susan
    Thomas, Deborah
    Newsome, Willie
    Kantarjian, Hagop
    BLOOD, 2009, 114 (22) : 436 - 436
  • [29] Clofarabine is active in combination with cytarabine (ara-C) in adult patients (pts) in first relapsed and primary refractory acute leukemia and high-risk myelodysplastic syndrome (MDS).
    Faderl, S
    Gandhi, V
    Garcia-Manero, G
    Thomas, DA
    Cortes, JE
    O'Brien, S
    Estey, E
    Craig, A
    Weiss, J
    Keating, M
    Verstovsek, S
    Giles, FJ
    Kwari, M
    Plunkett, W
    Kantarjian, HM
    BLOOD, 2003, 102 (11) : 615A - 615A
  • [30] Farnesyl transferase inhibitor (Tipifarnib, zarnestra; z) in combination with standard chemotherapy with idarubicin (Ida) and cytarabime (ara-C) for patients (pts) with newly diagnosed acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS).
    Alvarez, Ricardo H.
    Kantarijan, Hagop
    Garcia-Manero, Guillermo
    Estrov, Zeev
    Ravandi-Kashani, Farhad
    Verstovsek, Srdan
    Giles, Francis
    O'Brien, Susan
    Koller, Charles Asa
    Faderl, Stefan
    Thomas, Deborah
    Wright, John J.
    Cortes, Jorge
    BLOOD, 2006, 108 (11) : 565A - 566A
12345